SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for SolarWindow Technologies, (WNDW) — Jun 17, 2021

SolarWindow Technologies, Inc.
Date: June 17, 2021 · CIK: 0001071840 · Accession: 0000000000-21-007489

AI Filing Summary & Sentiment

File numbers found in text: 333-256983

Date
June 17, 2021
Author
Not clearly detected
Form
UPLOAD
Company
SolarWindow Technologies, Inc.

Letter

United States securities and exchange commission logo June 17, 2021 Jatinder Bhogal Chief Executive Officer SolarWindow Technologies, Inc. 430 Park Avenue, Suite 702 New York, NY 10022 Re:SolarWindow Technologies, Inc. Registration Statement on Form S-3 Filed June 10, 2021 File No. 333-256983 Dear Mr. Bhogal: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tom Kluck at 202-551-3233 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joseph Sierchio

Show Raw Text
United States securities and exchange commission logo
June 17, 2021
Jatinder Bhogal
Chief Executive Officer
SolarWindow Technologies, Inc.
430 Park Avenue, Suite 702
New York, NY 10022
Re:SolarWindow Technologies, Inc.
Registration Statement on Form S-3
Filed June 10, 2021
File No. 333-256983
Dear Mr. Bhogal:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tom Kluck at 202-551-3233 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Joseph Sierchio